List of FDA-approved peptides PDF The landscape of peptide therapy is undergoing significant shifts, driven by evolving FDA regulations. The FDA peptide ban update reflects a complex regulatory approach to compounded peptides, impacting their availability for therapeutic use作者：HP Works·2024—Specifically, the agency announced in October 2023 that severalpeptideswould be added to Category 2, which are considered “Bulk Drug .... While not all peptides are banned, many popular formulations used in compounding pharmacies are facing restrictions, leading to considerable confusion and concern among users and practitioners.2025年5月22日—Novo Nordisk is ramping up its war on compounders making versions of its top-selling semaglutide medicine as the regulatory grace period for their products ...
The U.S. Food and Drug Administration (FDA) has been actively reviewing and reclassifying various bulk drug substances, including a wide array of peptides. This has led to certain peptides being placed on lists that prohibit or restrict their use in compounding pharmacies.FDA Launches Green List to Protect Americans from Illegal ... The FDA's primary concern is ensuring the safety and efficacy of drug products available to the publicFrom January 2025, theFDAwill enforce revisions to its interim policy on bulk drug substances, limiting their use by compounding pharmacies. The move ends .... When a peptide is identified as posing "significant safety risks" or is not approved for human use, its compounding becomes problematic.
A key development has been the classification of certain peptides as "Substance with Safety Concerns" or being placed in Category 2 of the interim 503A bulks list. This designation means these substances are ineligible for compounding under current FDA guidance. For instance, substances like BPC-157 and TB-500 (Thymosin Beta-4) have been subject to these reclassifications, leading to pharmacies ceasing production of products containing them2024年2月29日—TheFDAreleased new regulations on 17 popularpeptidetreatments. Here's how to continue treatment or revamp your optimization protocol..
The regulatory changes have had a direct impact on widely discussed peptides, including those used in weight management and other therapeutic areas. While some headlines suggest a complete ban, the reality is more nuanced. The FDA has not instituted a universal ban; rather, it has clarified policies and enforced existing regulations more strictly. This means that while some peptides are prohibited for compounding, others may still be available if they meet specific criteria, such as having FDA approval or Generally Recognized as Safe (GRAS) status.
The situation is particularly relevant for compounded GLP-1 receptor agonists (GLP-1RAs) like semaglutide and tirzepatideA closer look at the unapproved peptide injections .... Although the FDA has indicated that shortages of some of these medications have been resolved, the agency continues to scrutinize marketing and manufacturing practices for compounded versions. This scrutiny has prompted policy changes and led to warnings against companies illegally selling unapproved drugs. Furthermore, the FDA has established a "green list" import alert to help prevent the entry of potentially dangerous GLP-1 drugs.
For individuals and practitioners relying on compounded peptides, staying informed about the latest FDA updates is crucialFDA clarifies policies for compounders as national GLP-1 .... The regulatory environment is dynamic, with decisions made by committees like the Pharmacy Compounding Advisory Committee (PCAC) influencing the availability of specific substances. For example, the FDA agreed to halt unilateral bans and submit certain key peptides for public review by the PCAC.
The FDA's actions aim to distinguish between peptides that have undergone rigorous clinical trials and received approval for specific indications and those that are compounded without such oversight. The agency has highlighted potential safety risks associated with reviewing nominations for bulk drug substances proposed for inclusion on the 503A or 503B bulks listsThe U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-likepeptide1 (GLP-1) medication, has been resolved..
The future of peptide therapy in the United States will likely involve a clearer distinction between FDA-approved peptide medications and compounded formulationsFDA's Overreach on Compounded Peptides: Legal Battles .... While the initial wave of regulatory action has caused disruption, it may ultimately lead to a more robust and transparent market for therapeutic peptides. The FDA continues to review substances, and some peptides previously restricted may be revisited. Public meetings and ongoing evaluations by advisory committees play a significant role in shaping these decisions. As the market adapts, the emphasis will likely shift towards peptides with established safety profiles and regulatory approval, ensuring patient safety remains paramount.
Join the newsletter to receive news, updates, new products and freebies in your inbox.